# Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/aha/123835) · 2026-11-11 · Medicine
Page: https://themorning.science/story/novel-glucagon-glp-1-agonist-meets-cardiovascular-safety-endpoint-8b4c8669d529d50f
Kind: research · Impact: medium

## In brief

- Survodutide, an investigational glucagon and GLP-1 receptor dual agonist, met a cardiovascular safety endpoint in a trial of patients with obesity.
- Participants had established cardiovascular disease, chronic kidney disease, or increased risk of cardiovascular disease.
- The source reports the drug was safe for these patients; it is not yet an approved therapy.

## Why it matters

The result addresses a key safety requirement for new obesity drugs in patients with heart and kidney risk, a population where safety data are critical before wider use.

## Timeline

- 2026-11-11: MedPage Today reports that survodutide met the cardiovascular safety endpoint, presented at AHA meeting coverage

## Coverage

- [Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint](https://www.medpagetoday.com/meetingcoverage/aha/123835) — MedPageToday.com - medical news for physicians, 2026-11-11

Tags: obesity, cardiovascular safety, glucagon receptor, glp-1, clinical trial

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science